Pfizer's Maraviroc To Receive Accelerated Regulatory Reviews In The U.S. And Europe

Pfizer announced today that
marketing authorization applications for maraviroc will receive accelerated
review in both the United States and Europe. Accelerated reviews are
granted to potential medicines that, if approved, would represent
significant improvements over current therapies.


If approved by the regulatory agencies, maraviroc will be the first in
a new class of HIV/AIDS treatments called CCR5 antagonists that work by
blocking viral entry. Rather than fighting HIV inside white blood cells,
CCR5 antagonists prevent the virus produced by infected cells from entering
uninfected cells by blocking its predominant entry route, the CCR5 co-
receptor.



"There is a profound global need for new medicines to help HIV/AIDS
patients," said John LaMattina, president, Pfizer Global Research and
Development. "We expect that CCR5 antagonists, like maraviroc, will become
critically important new treatment options for patients who are resistant
or intolerant to their current HIV/AIDS therapies."



The U.S. Food and Drug Administration (FDA) priority review process
takes place within a six-month period. Pfizer submitted the U.S. and EU
maraviroc marketing applications in December 2006. An FDA Advisory Panel is
scheduled for April 24. Pfizer has begun pursuing regulatory approval for
maraviroc in other countries to enable broad access to the drug.



Moving with Urgency



The discovery of maraviroc dates back to 1997 when Pfizer research
scientists in Sandwich, UK designed the molecule following the publication
of two significant research findings. A study was published in 1996 that
described resistance to HIV-1 infection in certain Caucasian subjects, and
in the same year, another journal reported the binding of HIV to the CCR5
receptor. Scientists noted that about one percent of Europeans who lacked
the genes for CCR5 receptors were the very ones who were resistant to
acquiring HIV infection. This finding suggested that blocking the virus's
entry through this gateway may lead to a breakthrough therapy. Based on
these emerging scientific insights and patient need, the maraviroc team
significantly accelerated development time.



"This is the kind of targeted science that underscores our commitment
to research and development in a range of infectious diseases where there
is high human cost due to drug resistance," said Dr. Ethan Weiner, senior
vice president, Pfizer Global Research and Development. "Maraviroc is an
outstanding example of rapid development and continuous innovation through
which Pfizer researchers quickly translated a scientific hypothesis into a
promising compound in this area of great medical need."



Maraviroc is the seventh Pfizer new drug application to receive
"Priority Review" status from the FDA over the past two years. Other
priority review FDA approvals include Sutent for advanced kidney cancer and
gastrointestinal stromal tumors, Chantix for smoking cessation, Revatio for
pulmonary arterial hypertension, and Macugen for age-related macular
degeneration which can lead to blindness in elderly patients.
















Pivotal Trials



The marketing applications follow Pfizer's review of efficacy and
safety data from two pivotal phase 3 trials. The trials, MOTIVATE-1 and 2
(Maraviroc plus Optimized Therapy In Viremic Antiretroviral
Treatment-Experienced patients), represent 24-week data comparing Optimized
Background Therapy, with or without maraviroc, in over 1,000 highly
treatment-experienced patients with CCR5-tropic HIV-1. These study results
have been accepted for presentation at an upcoming HIV conference.



In addition, the independent Data Safety Monitoring Board (DSMB) for
maraviroc met on January 15, 2007 and continues to monitor the ongoing
clinical program. The DSMB recommended that the maraviroc Phase 3
registrational trials, in both treatment-na??ve and treatment-experienced
patients, continue as currently designed.



Update on Expanded Access Program



In December 2006, Pfizer announced plans to establish a multi-national
Expanded Access Program to provide maraviroc to patients with limited
available treatment options based on its safety and efficacy observed in
clinical trials to date. The program is now open for enrollment with a
target to enroll patients from over 30 countries.



Through partnerships and focused philanthropic efforts, Pfizer strives
to support HIV prevention efforts, build improved healthcare
infrastructure, and further access to HIV/AIDS medicines. Current
initiatives include the U.S. Southern States HIV/AIDS Prevention
Initiative; the building of the Infectious Disease Institute in Kampala,
Uganda; the Pfizer Global Health Fellows Program; and the Diflucan(R)
Partnership Program. For more information on these and other Pfizer
initiatives, go to pfizer.



The information contained in this release is as of
February 13, 2007. Pfizer assumes no obligation to update any
forward-looking statements contained in this release as the result of new
information or future events or developments.



This release contains forward-looking information that involves
substantial risks and uncertainties regarding a product candidate,
including its potential benefits, that is under review by the United States
Food and Drug Administration (FDA), the European Medicines Evaluation
Agency (EMEA) and certain other regulatory authorities. Such risks and
uncertainties include, among other things, whether and when the FDA, the
EMEA and other regulatory authorities will approve the product candidate,
their decisions regarding labeling and other matters that could affect its
availability or commercial potential, as well as competitive developments.



A further list and description of risks and uncertainties can be found
in Pfizer's Annual Report on Form 10-K for the fiscal year ended December
31, 2005 and in its reports on Form 10-Q and Form 8-K.


Pfizer Inc

pfizer


View drug information on Chantix; Macugen; Sutent.